Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume – What’s Next?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) saw unusually-strong trading volume on Tuesday . Approximately 448,209 shares changed hands during trading, a decline of 5% from the previous session’s volume of 472,318 shares.The stock last traded at $15.01 and had previously closed at $15.43.

Trending Headlines about Silence Therapeutics

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: Silence Therapeutics reported positive top-line results from the Phase 2 SANRECO trial of divesiran in 48 phlebotomy-dependent patients with polycythemia vera. The treatment met its primary and secondary endpoints, supporting management’s view that divesiran could have a best-in-class profile and strengthening the company’s lead clinical program. Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial
• Positive Sentiment: The trial outcome triggered investor optimism and a sharp move higher in the stock, with coverage highlighting the potential of divesiran to treat polycythemia vera and other blood disorders. Management discussed the results in an investor presentation and conference-call transcript. Silence Therapeutics stock surges as divesiran trial results fuel optimism
• Neutral Sentiment: Analysts assigned Silence Therapeutics a consensus “Moderate Buy” rating, indicating generally favorable expectations but not unanimous bullish conviction. Silence Therapeutics Given Consensus Rating of Moderate Buy
• Negative Sentiment: The company launched a proposed underwritten public offering of approximately $150 million of American Depositary Shares. While the proceeds could support clinical development, the offering may dilute existing shareholders and create near-term selling pressure. Silence Therapeutics Announces Proposed Public Offering
• Negative Sentiment: Second-quarter results were weaker than expected: Silence reported a loss of $0.26 per share versus the $0.14 consensus loss estimate. The company remains unprofitable, increasing the importance of financing and successful development of its pipeline. Silence Therapeutics Reports Second Quarter 2026 Results

Analysts Set New Price Targets

Several equities research analysts have commented on SLN shares. Cantor Fitzgerald started coverage on Silence Therapeutics in a research note on Wednesday, June 24th. They set an “overweight” rating for the company. Morgan Stanley restated an “overweight” rating and issued a $32.00 price objective (up from $25.00) on shares of Silence Therapeutics in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Silence Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $53.50.

Silence Therapeutics Stock Performance

The company has a 50-day moving average of $9.49 and a 200-day moving average of $7.25. The stock has a market capitalization of $733.87 million, a price-to-earnings ratio of -9.70 and a beta of 1.39.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%. As a group, analysts expect that Silence Therapeutics PLC Sponsored ADR will post -1.08 earnings per share for the current year.

Institutional Trading of Silence Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in shares of Silence Therapeutics by 18.1% during the second quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock worth $121,000 after purchasing an additional 1,698 shares during the last quarter. Seven Fleet Capital Management LP increased its stake in shares of Silence Therapeutics by 6.2% during the 1st quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company’s stock valued at $826,000 after acquiring an additional 9,159 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Silence Therapeutics by 903.8% in the first quarter. Bank of America Corp DE now owns 29,773 shares of the company’s stock worth $157,000 after acquiring an additional 26,807 shares during the last quarter. ADAR1 Capital Management LLC raised its stake in Silence Therapeutics by 628.2% during the first quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock worth $907,000 after purchasing an additional 148,514 shares during the period. Finally, SG Americas Securities LLC increased its holdings in shares of Silence Therapeutics by 11.8% during the 1st quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock worth $1,511,000 after buying an additional 30,358 shares during the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.